Table 3

Multivariate analyses of prognostic factors correlated with PFS and OS

Variables	Progression-free survival				Over survival
	Training cohort		Validation cohort		Training cohort		Validation cohort
	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
Necrosis present/absent	1.00 (0.55 to 1.80)	0.995	1.27 (0.71 to 2.27)	0.429	0.97 (0.53 to 1.77)	0.911	1.35 (0.73 to 2.51)	0.335
MVI present/absent	0.95 (0.48 to 1.88)	0.872	1.64 (0.90 to 2.99)	0.108	0.58 (0.27 to 1.25)	0.167	1.45 (0.77 to 2.76)	0.252
Fuhrman grade high/low	1.45 (0.77 to 2.73)	0.251	1.93 (1.09 to 3.39)	0.023	1.50 (0.79 to 2.87)	0.217	2.04 (1.13 to 3.68)	0.018
TNM stage high/low	5.14 (2.67 to 9.91)	< 0.001	2.00 (1.14 to 3.51)	0.016	5.26 (2.72 to 10.18)	< 0.001	2.02 (1.10 to 3.69)	0.023
HHLA2 positive/negative	2.10 (1.11 to 3.99)	0.023	2.12 (1.22 to 3.71)	0.008	2.14 (1.11 to 4.15)	0.024	2.08 (1.16 to 3.74)	0.014
PD-L1 positive/negative	2.28 (1.30 to 3.99)	0.004	1.61 (0.93 to 2.77)	0.087	2.27 (1.26 to 4.09)	0.006	1.66 (0.94 to 2.95)	0.081

*P values <0.05 in bold are statistically significant.
HHLA2, human endogenous retrovirus-H long terminal repeat-associating protein 2; MVI, microvascular invasion; OS, overall survival; PD-L1, programmed death 1 ligand 1; PFS, progression-free survival.